CUMYL-CBMINACA

CUMYL-CBMINACA (also known as SGT-153) is a synthetic cannabinoid that has been identified in illicit products. It is a potent agonist of the CB1 receptor and CB2 receptor with binding affinity similar to that of JWH-018. CUMYL-CBMINACA is a derivative of CUMYL-PINACA with an indazole-3-carboxamide moiety replacing the tetramethylcyclopropyl group.

Chemistry

CUMYL-CBMINACA is a member of the class of indazoles that is 1H-indazole-3-carboxamide substituted at position 1 by a cumyl group and at position 3 by a 1-(5-fluoropentyl)-1H-indol-3-yl group. It has a role as a synthetic cannabinoid and a hallucinogen.

Pharmacology

CUMYL-CBMINACA acts as a potent agonist for the CB1 receptor (Ki = 2.6 nM, EC50 = 0.58 nM) and the CB2 receptor (Ki = 0.58 nM, EC50 = 0.21 nM). It has been reported to have a binding affinity that is 5 times greater for the CB1 receptor than that of JWH-018.

Legality

CUMYL-CBMINACA is a controlled substance in some countries due to its potential for abuse. In the United States, it is a Schedule I controlled substance. In the United Kingdom, it is a Class B drug under the Misuse of Drugs Act 1971.

See also

• CUMYL-PINACA
• CUMYL-THPINACA
• CUMYL-PEGACLONE
• Synthetic cannabinoids
• Indazole

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia